GOVX Corporate Update soon | 10X Upside Potential Analyst Rating

GOVX GeoVax Labs is a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer.
GeoVax Labs will report Q1 2022 financial results on April 27.

Jason McCarthy from Maxim Group has a $10.00 price target for GOVX.
The stock is now $1.01.
Market Cap of only 7.23Mil.

This is a 4X upside potential short term stock in my opinion.

biotechbiotechnologycancercancervaccineFundamental AnalysisgeovaxGOVXTechnical IndicatorspennystocksTrend Analysisvaccinevaccinestocks

Juga pada:

Penafian